SEC Comment Letter for CEL SCI CORP (CVM) (CIK 0000725363) (CVM) — Apr 4, 2017
CEL SCI CORP (CVM) (CIK 0000725363)
Date: April 4, 2017 · CIK: 0000725363 · Accession: 0000000000-17-011304
AI Filing Summary & Sentiment
Show Raw Text
April 3, 2017
Geert Kersten
Chief Executive Officer
Cel-Sci Corporation
8229 Boone Blvd.
Suite 802
Vienna, Virginia 22182
Cel-Sci Corporation
Preliminary Proxy Statement on Schedule 14A
Filed on March 17, 2017
File No. 001-11889Re:
Dear Mr. Kersten:
We have limited our review of your preliminary proxy statement to the issues we have
addressed in our comments. Please respond to this letter by revising the proxy statement and
providing the requested information. If you do not believe our comments apply to your facts and
circumstances, please tell us why in your response.
After reviewing your response to these comments, we may have additional comments.
PRE 14A filed March 17, 2017
Proposal to Give the Board of Directors the Authorization to Reverse Split..., page 25
Your disclosure on page 27 that fractional shares will be rounded up to the nearest whole
share appears inconsistent with your disclosure that a ratio of 1-for-25 would eliminate
558 shareholders of record causing the company to have 260 holders of record. Please
revise to clarify why shareholders would be eliminated if you are rounding up. If
fractional shares will be cashed out, please expand your disclosure to provide the terms of
the cash out.1.
Given your disclosure that a ratio of 1-for-25 would eliminate 558 shareholders of record
causing the company to have 260 holders of record, it appears that the reverse stock split
may have a reasonable likelihood of cashing out a sufficient number of record holders to
produce one or both effects reflected in Rule 13e-3(a)(3)(ii)(A) and (B). Accordingly,
please provide your analysis as to whether the contemplated reverse stock split, cashing
out of fractional shares and the potential reduction in the number of record holders may2.
Geert Kersten
Cel-Sci Corporation
2 PageApril 3, 2017
constitute a going private transaction pursuant to Rule 13e-3. If so, please comply with
the requirements set forth in paragraphs (d), (e), and (f) of Rule 13e-3. Alternatively,
please advise us why the potential split ratio chosen would not be reasonably likely to
produce either of the referenced effects.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
You may contact Johnny Gharib at (202) 551-3170 or Joseph McCann at (202) 551-
6262 if you have any questions.
Division of Corporation Finance
Office of Healthcare & Insurance